- How innovation supply chains could fill empty pipelines
Drugmakers have steadily reduced research and development budgets and turned to mergers, acquisitions, partnerships and, increasingly, their own venture capital funds to develop new drugs. But the strategy is lacking because it does not get drugmakers involved early enough in an innovation's development, writes Noubar Afeyan, founder, managing partner and CEO of Flagship Ventures. What is needed is an innovation supply chain that would force drugmakers to better define requirements and cultivate innovation development in the beginning stages, Afeyan writes. Xconomy/Boston (6/26)        | Webcast: A Conversation with The Johns Hopkins Hospital on Lowering the Cost of Healthcare from Inside Out
Learn how The Johns Hopkins Hospital uses its Integrated Asset and Service Management solution to improve uptime to support patient care; control costs for procurement, maintenance, labor and materials; support regulatory compliance activities; and use workflow capabilities for internal controls. Watch the webcast. |
 | Health Care & Policy |  |  | | - Baxter's hemophilia B drug wins FDA approval
Baxter International obtained the FDA's approval to market Rixubis, a purified protein that comes in freeze-dried powder, for routine and perioperative prevention and control of bleeding in adults with hemophilia B. The genetically engineered recombinant factor IX is the first treatment cleared for the genetic condition in more than 15 years. Reuters (6/27), HealthDay News (6/27), RTT News (6/27) - Celgene, MorphoSys sign antibody drug deal worth up to $818M
Celgene and MorphoSys will collaborate in the development of the latter's fully human monoclonal antibody MOR202 for treatment of multiple myeloma and other indications in a deal worth as much as $818 million. The drug, which targets the CD38 protein, is in a Phase I/IIa study against relapsed/refractory melanoma. MorphoSys will get $92 million upfront and a $60 million investment from Celgene, in addition to possible milestone fees and sales royalties. PharmaTimes (U.K.) (6/27), Genetic Engineering & Biotechnology News (6/27) - Vivus' Spedra for erectile dysfunction wins EU approval
The European Commission granted Vivus approval to market its PDE5 inhibitor Spedra, or avanafil, as a treatment for erectile dysfunction. The approval makes Spedra the first chemical entity cleared for treatment of ED in more than 10 years. The drug was approved in the U.S. more than a year ago, but has yet to be commercialized as Vivus looks for a partner. PharmaTimes (U.K.) (6/26) - BioMérieux gains CE mark for advanced immunoassay platform
European regulators have given bioMérieux the go-ahead to market a third-generation version of its VIDAS immunoassay platform, which can be used to detect infectious disease serums and other types of biomolecules. The technology improves on the older models with a preanalytical section as well as automation and better quality control. MedGadget.com (6/26) | Company & Financial News | | | | - Merck sells API business, drug portfolio in $1B deal
Aspen Group agreed to buy Merck & Co.'s active pharmaceutical ingredient manufacturing business and purchase an option to buy a portfolio of 11 finished dose form molecules that target a range of conditions. The deal is valued at $1 billion. Aspen said the acquisition, which is expected to be finalized this year, will bolster its growth in Latin America, the Asia-Pacific region and other emerging markets. Bloomberg (6/27), Pharmaceutical Business Review Online (6/28) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Poll: Most Americans support biofuels, RFS
According to a new Fuels America poll, 80% of Americans think the U.S. should use more renewable fuel and 73% believe the Renewable Fuel Standard is helping to achieve that goal. If gasoline prices go up, 55% said they will take fewer road trips, 27% will go out to restaurants less often, 17% will cut spending on clothing and 12% will spend less on gifts, according to the survey. About 75% of those surveyed said they want more renewable fuel options when they go to fill up. DomesticFuel.com (6/26), The Baltimore Sun (6/26), United Press International (6/27) | News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy suppliers for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | Originality is unexplored territory. You get there by carrying a canoe -- you can't take a taxi."
--Alan Alda,
American actor  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, June 27, 2013
- Wednesday, June 26, 2013
- Tuesday, June 25, 2013
- Monday, June 24, 2013
- Friday, June 21, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment